Kathy Rowlen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

InDevR a top provider of analytical technologies for vaccines and biotherapeutics has raised $9 million infinancing.

I Investigating the cause of a disease is like investigating the cause of a crime. Just as the detection of a suspect's DNA at a crime scene doesn't prove they committed the crime, so the detection of the DNA of a virus in a patient doesn't prove...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

The ongoing pandemic has created a wealth of interest from venture capital investors and the broader public in what biotech companies are able to achieve if it’s flush with resources. That was the sentiment of a group of Boulder area biotechnology industry leaders, who met virtually at BizWest’s CEO Roundtable on the biotechnology industry Tuesday morning. Steady stream of investor dollars Biotech was one of the few industries that was relatively unaffected from a financial standpoint during the pandemic, and multiple companies marked significant financial milestones just in the past few ...

InDevR Expands Commercial Portfolio for Coronavirus Vaccine Characterization USA - English Share this article Share this article BOULDER, Colo., Dec. 10, 2020 /PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Spike Protein Kit and SARS-CoV-2 Spike Protein Standard for vaccine antigen quantification. Of the many coronavirus vaccine candidates in development, several are based on either whole virus or recombinant spik...